Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

87 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-06

Study Completion Date

2024-05-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Electroconvulsive therapy (ECT) is the treatment of choice for drug-resistant depression (30% of patients), or when there is a short-term risk to the patient's life. Despite its robust efficacy and rapid onset of action, its use is limited both by the limited range of treatment available and by the cognitive effects sometimes induced. The present study focuses on the links between the efficacy of ECT, its cognitive effects and the formation of new neurons in the hippocampus (hippocampal neurogenesis) associated with this treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy

NCT02715986

Severe Depression

COMPLETED NA

Mechanism of Action of Electroconvulsive Therapy

NCT04059952

Unipolar Depression Bipolar Depression

COMPLETED

Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression

NCT02530164

Major Depressive Disorder Unipolar Depression Depression

COMPLETED NA

Multimodal Imaging of ECT Effects

NCT02871141

Major Depressive Disorder

COMPLETED

Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

NCT05905705

Treatment Resistant Depression

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder (MDD) Bipolar Disorder Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Depressed patient treated with electroconvulsivotherapy

The indication for ECT treatment is established by the department's medical team. Participants are not assigned to ECT as part of this observational study.

No interventions assigned to this group

Depressed patient treated without electroconvulsivotherapy

The indication for antidepressant treatment is established by the department's medical team. Participants are not assigned to ECT as part of this observational study.

No interventions assigned to this group

Healthy volunteers

Age- and sex-matched healthy volunteers free of psychiatric disorders.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Study population: depressed subjects treated with ECT

* Male or female over 18 years of age
* Hospitalised at the Centre Hospitalier Sainte-Anne
* Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
* Indication for ECT treatment
* Patient has given informed written consent
* Beneficiary of a social security scheme
2. Control population: depressed subjects treated without ECT

* Male or female over 18 years of age
* Hospitalised at the Centre Hospitalier Sainte-Anne
* Suffering from a unipolar or bipolar major depressive episode, according to DSM5 criteria
* Patient who has given informed written consent
* Beneficiary of a social security scheme
3. Control population: healthy volunteers

* Male or female over 18 years of age
* Patient with written informed consent
* Beneficiary of a social security scheme

Exclusion Criteria

1. Study population: depressed subjects with ECT

* Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on a substance other than tobacco
* Neurological comorbidity: Parkinson's disease, dementia
* ECT treatment in the 6 months prior to inclusion
* Compulsory care
* Protected adults, persons under court protection measures
* Persons deprived of liberty by judicial or administrative decision;
* Refusal of consent to ECT treatment
* Contraindications to ECT (HTIC, recent history of stroke, severe uncontrolled arterial hypertension, contraindication to anaesthesia)
* Contraindications to MRI (patients with metal prostheses, claustrophobia)
* Pregnant or breast-feeding women
2. Control population: depressed subjects without ECT

* Psychiatric comorbidity: schizophrenia, pervasive developmental disorder, dependence on any substance other than tobacco
* Neurological comorbidity: Parkinson's disease, dementia
* ECT treatment in the 6 months prior to inclusion
* Compulsory care
* Protected adults, persons under court protection measures
* Persons deprived of liberty by judicial or administrative decision;
* Pregnant or breast-feeding women
3. Control population: healthyvolunteers

* Protected adults, persons under legal protection,
* Persons deprived of their liberty by judicial or administrative decision ;
* persons hospitalised for purposes other than research
* Clear psychiatric history
* Dependence on any substance other than tobacco
* Neurological history: Parkinson's disease, dementia
* Pregnant or breast-feeding women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes